...
首页> 外文期刊>Cardiovascular engineering and technology. >Biological Equivalence of GGTA-1 Glycosyltransferase Knockout and Standard Porcine Pericardial Tissue Using 90-Day Mitral Valve Implantation in Adolescent Sheep
【24h】

Biological Equivalence of GGTA-1 Glycosyltransferase Knockout and Standard Porcine Pericardial Tissue Using 90-Day Mitral Valve Implantation in Adolescent Sheep

机译:GGTA-1 糖基转移酶敲除和标准猪心包组织的生物学等效性,使用 90 天二尖瓣植入青春期绵羊

获取原文
获取原文并翻译 | 示例

摘要

Objective-There is growing interest in the application of genetically engineered reduced antigenicity animal tissue for manufacture of bioprosthetic heart valves (BHVs) to reduce antibody induced tissue calcification and accelerated structural valve degeneration (SVD). This study tested biological equivalence of valves made from Gal-knockout (GalKO) and standard porcine pericardium after 90-day mitral valve implantation in sheep. Methods -GalKO (n = 5) and standard (n = 5) porcine pericardial BHVs were implanted in a randomized and blind fashion into sheep for 90-days. Valve haemodynamic function was measured at 30-day intervals. After explantation, valves were examined for pannus, vegetation, inflammation, thrombus, and tissue calcification. Results- Nine of 10 recipients completed the study. There was no difference between study groups for haemodynamic performance and no adverse valve-related events. Explanted BHVs showed mild pannus integration and minimal thrombus, with no difference between the groups. Limited focal mineral deposits were detected by x-ray. Atomic spectroscopy analysis detected tissue calcium levels of 1.0 mu g/mg +/- 0.2 for GalKO BHVs and 1.9 mu g/mg +/- 0.9 for standard tissue BHVs (p = 0.4), considered to be both low and equivalent. Conclusions-This is the first demonstration of biological equivalence between GalKO and standard pig pericardium. The GalKO mutation causes neither intrinsic detrimental biological nor functional impact on BHV performance. Commercial adaptation of GalKO tissue for surgical or transcatheter BHVs would remove the clinical disparity between patients producing anti-Gal antibody and BHVs containing the Gal antigen. GalKO BHVs may reduce accelerated tissue calcification and SVD, enhancing patient choices, especially for younger patients. GRAPHICS .
机译:目的-对基因工程降低抗原性动物组织在生物人工心脏瓣膜(BHVs)制造中的应用越来越感兴趣,以减少抗体诱导的组织钙化和加速结构瓣膜变性(SVD)。本研究测试了由Gal敲除(GalKO)和标准猪心包制成的瓣膜在绵羊二尖瓣植入90天后的生物学等效性。方法 -将GalKO(n = 5)和标准(n = 5)猪心包BHVs以随机盲法植入绵羊体内,持续90 d。每隔 30 天测量一次瓣膜血流动力学功能。移植后,检查瓣膜是否有翳、赘生物、炎症、血栓和组织钙化。结果- 10 名接受者中有 9 名完成了研究。研究组之间的血流动力学表现和无不良瓣膜相关事件没有差异。外植的BHVs显示出轻度的翳整合和最小的血栓,两组之间没有差异。通过 X 射线检测到有限的局灶性矿床。原子光谱分析检测到GalKO BHVs的组织钙水平为1.0 μg/mg +/- 0.2,标准组织BHVs的组织钙水平为1.9 μg/mg +/- 0.9(p = 0.4),被认为是低的和等效的。结论-这是GalKO与标准猪心包生物学等效性的首次证明。GalKO 突变不会对 BHV 性能造成内在有害的生物学或功能影响。将 GalKO 组织用于手术或经导管 BHV 的商业化将消除产生抗 Gal 抗体的患者与含有 Gal 抗原的 BHV 之间的临床差异。GalKO BHV 可以减少加速的组织钙化和 SVD,增加患者的选择,尤其是对于年轻患者。[图形] .

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号